NeoGenomics, Inc. operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It provides testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories. Its offerings include cytogenetics, fluorescence in-situ hybridization, flow cytometry, immunohistochemistry, digital imaging, and molecular testing, as well as morphologic analysis and support for pharmaceutical clients' oncology programs. The company was founded in 2001 and is headquartered in Fort Myers, Florida.
NeoGenomics rides new FDA test, raised guidance, and CEO transition
▲
FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.
New product launch is a fresh growth driver that directly boosts revenue potential.
Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.
Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.
Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.
Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.
CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.
Leadership change is a new event that can affect investor confidence and future strategy.
RadNet posted the strongest quarter among the five testing and diagnostics services stocks tracked, reporting revenues of $622.7 million, up 25% year on year and 2.3% above analysts' expectations, with a beat on EPS estimates. Dr. Howard Berger, President and Chief Executive Officer of RadNet, said the Imaging Center and Digital Health reportable operating segments continued to demonstrate strong growth and achieve record quarterly results, with Total Company Revenue up 25.0% and Digital Health segment Revenue up 56.5% from last year's same quarter. As a group, the five testing and diagnostics services stocks tracked beat analysts' consensus estimates by 2.8%, and their share prices are up 7.2% on average since the latest earnings results. Quest Diagnostics reported revenues of $3.04 billion, up 10.2% year on year and 2.3% above expectations, while Guardant Health reported revenues of $335 million, up 44.3% year on year and 6.4% above expectations, scoring the biggest analyst estimate beat, fastest revenue growth, and highest full-year guidance raise of the whole group. Labcorp delivered the weakest performance against analyst estimates, slowest revenue growth, and weakest full-year guidance update among its peers, with revenues of $3.73 billion, up 5.8% year on year and in line with analysts' expectations, while NeoGenomics reported revenues of $201.7 million, up 11.2% year on year and 2.2% above expectations.
Biotech & Genomic Medicine › Diagnostics & Precision Testing ▲Demand
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO ▲Demand
RDNT · Capital · Positive RadNet posted the strongest quarter in the group with revenues up 25% year on year and beats on revenue and EPS.
DGX · Capital · Positive Quest Diagnostics reported revenues of $3.04 billion, up 10.2% year on year and 2.3% above expectations.
GH · Capital · Positive Guardant Health reported revenues of $335 million, up 44.3% year on year, scoring the biggest estimate beat and fastest growth in the group.
LH · Capital · Negative Labcorp delivered the weakest performance against estimates, slowest revenue growth, and weakest full-year guidance among peers.
NEO · Capital · Positive NeoGenomics reported revenues of $201.7 million, up 11.2% year on year and 2.2% above expectations.
NeoGenomics Guides to About US$209 Million Q3 2026 Revenue, Names Warren Stone CEO
NeoGenomics, Inc. issued preliminary third-quarter 2026 revenue guidance of about US$209 million with very strong next-generation sequencing growth and outlined plans to increase its full-year revenue guidance. The company also amended its bylaws to expand its Board to up to eleven directors. In a planned leadership transition, President and COO Warren Stone will become CEO and join the Board in January 2027, while current CEO Tony Zook moves to Executive Chair and the Board refreshes its independent leadership. The stronger revenue outlook, particularly in NGS, supports the near-term revenue catalyst but does not materially change the central risk that high fixed costs and heavy investment could weigh on margins if volumes soften or funding pressures persist. NeoGenomics' narrative projects $997.4 million revenue and $64.1 million earnings by 2029, with a $19.72 fair value estimate.
Google Signs Nuclear Power Deal With Constellation Energy Worth Over $4.3 Billion
Google announced a major long-term power agreement with Constellation Energy, under which it will buy power tied to 890 megawatts of new nuclear capacity alongside a separate 2,700-megawatt supply agreement, supporting more than $4.3 billion in new Constellation investment. Constellation Energy shares jumped more than 6% premarket on the news, while Alphabet rose about 0.5%. Separately, Option Care Health shares surged more than 20% following a Financial Times report that McKesson and private equity firm Clayton Dubilier & Rice are in advanced talks to jointly acquire the infusion services provider in a transaction valued at more than $5 billion; McKesson stock is up 1.5%. Berkshire Hathaway disclosed in a regulatory filing that it purchased about 2.4 million shares of Lennar, sending Lennar up 1.5%. NeoGenomics rose 5% after announcing that current President and COO Warren Stone will take the helm from Tony Cook in January 2027, and reporting preliminary third-quarter total revenue of $209 million, topping the $205.9 million consensus estimate, per FactSet. Advanced Micro Devices rose nearly 2% after Citi raised its price target to $800, citing greater CPU demand driven by Meta's Muse AI agent, while Procter & Gamble rose 1.2% on an Evercore ISI upgrade to outperform and a price target increase to $166 from $161, and Corteva rose nearly 3% after JPMorgan upgraded the stock to overweight from neutral with a $19 price target.
CEG · Demand · Positive Google signed a long-term power agreement with Constellation for 890 MW of new nuclear capacity plus a 2,700 MW supply deal, supporting over $4.3 billion in new Constellation investment.
OPCH · Capital · Positive Option Care Health surged over 20% on an FT report that McKesson and Clayton Dubilier & Rice are in advanced talks to acquire it for over $5 billion.
MCK · Capital · Positive McKesson is in advanced talks to jointly acquire Option Care Health in a deal valued over $5 billion, with its stock up 1.5%.
NEO · Capital · Positive NeoGenomics rose 5% after announcing a CEO succession and preliminary Q3 revenue of $209M topping the $205.9M consensus.
PG · Capital · Positive Procter & Gamble rose 1.2% on an Evercore ISI upgrade to outperform and a price target increase to $166 from $161.
GOOG · Demand · Positive Alphabet's Google signed a major long-term nuclear power purchase agreement with Constellation to supply its operations.
NeoGenomics names Warren Stone CEO as Tony Zook moves to Executive Chairman
NeoGenomics Inc announced a CEO transition that will see President and Chief Operating Officer Warren Stone become CEO and join the Board effective January 4, 2027, while Tony Zook remains CEO through January 3, 2027, before transitioning to Executive Chairman. The Fort Myers, Florida-based oncology diagnostics company also reported preliminary unaudited third quarter revenue of approximately $209 million, surpassing the consensus analyst estimate of $205.89 million, with next-generation sequencing revenue growth of approximately 28% year over year for the quarter. Despite the revenue beat, NeoGenomics reiterated its full-year total revenue and adjusted EBITDA guidance previously provided on July 28, 2026, rather than raising it, and said further details, including an expected increase to full-year total revenue guidance resulting from third quarter performance, will be provided on the third quarter earnings call. In conjunction with the transition, Lynn Tetrault, current Chair and a Board member since 2015, will step down as Chair effective January 4, 2027, continue as an independent director until the 2027 Annual Meeting of Stockholders, and not stand for reelection, with Michael Kelly serving as Lead Independent Director effective January 4, 2027. Stone, 54, has over three decades of Life Sciences and Diagnostics leadership experience, including senior roles at Ortho Clinical Diagnostics and MilliporeSigma/Merck KGaA, and has held positions of increasing responsibility since joining NeoGenomics in 2022. Shares fell 3.6% in after-hours trading Monday following the announcement.
Biotech & Genomic Medicine › Diagnostics & Precision Testing Talent
Biotech & Genomic Medicine › Tools, Diagnostics & CDMO Talent
NEO · Capital · Neutral Q3 revenue beat ($209M vs $205.89M consensus) with 28% NGS growth, but full-year guidance reiterated rather than raised and shares fell 3.6% after-hours.
SciSparc, Avantor, NeoGenomics Lead Biotech Gains on Milestones and Upgraded Outlooks
Several biotech stocks posted sharp gains on Wednesday, led by SciSparc after its subsidiary completed internal validation of a quantum sampling platform for clinical trial data. SciSparc closed at $9.09, up 70.54%, following the announcement that NeuroThera Labs successfully validated the platform being advanced by CliniQuantum, in which NeuroThera holds a 54.01% ownership interest. Avantor rose 15.78% to $14.38 after reporting second-quarter net sales of $1.69 billion and raising its full-year adjusted EPS guidance to $0.80 to $0.83 from $0.77 to $0.83. NeoGenomics gained 13.96% to $15.27 after second-quarter consolidated revenue increased 11% to $202 million and the company lifted its full-year revenue outlook to $802 million to $806 million from $797 million to $803 million. Alvotech climbed 13.87% to $3.53 after the FDA classified the inspection of its Reykjavik manufacturing facility as Voluntary Action Indicated, a step forward for its biosimilar applications. Sanara MedTech surged 13.55% to $30.25 after agreeing to be acquired by MiMedx Group in a cash-and-stock deal valued at $35 per share, or about $350 million in total enterprise value. LB Pharmaceuticals advanced 11.62% to $39.00 after securing a $150 million private placement and accelerating the timeline for topline results from its Phase 3 schizophrenia trial to the first half of 2027.
NeoGenomics raises 2026 revenue guidance to $802M-$806M on clinical strength
NeoGenomics raised its full-year 2026 revenue guidance to a range of $802 million to $806 million, driven by strong clinical performance and durable growth in next-generation sequencing. Total second-quarter revenue reached $201.7 million, up 11% year-over-year and approximately $4 million above prior guidance, while adjusted EBITDA rose 36% to $14.4 million. Clinical revenue grew 14%, with NGS revenue surging 26% and now comprising one-third of clinical revenue, prompting management to lift its NGS growth forecast to the mid-20s from the prior low-20s estimate. The company lowered expectations for its nonclinical segment, now projecting a high-single-digit decline in 2026 versus the earlier low-to-mid-single-digit decline, as pharma revenue fell 26% in the quarter. NeoGenomics also raised its full-year adjusted EBITDA guidance to $56 million to $58 million and expects 100 to 150 basis points of gross margin improvement, supported by Lab of the Future efficiencies and a commercial reorganization into dedicated oncology and pathology teams.
NeoGenomics Launches FDA-Approved PTEN Test, Stock Seen as Slightly Undervalued
NeoGenomics has launched PTEN IHC CDx, an FDA-approved companion diagnostic that identifies prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. The stock has returned 40.75% over the past 30 days and 134.13% over one year, though three- and five-year total shareholder returns remain negative. Based on a widely followed narrative, NeoGenomics is priced just below an estimated fair value of $15.06 versus the last close at $14.61, implying the stock is about 3% undervalued. However, the current price-to-sales ratio of 2.6 times sits well above the US healthcare industry average of 1.5 times and the peer average of 1.1 times, which could weigh on momentum if sentiment cools.
NeoGenomics Launches First FDA-Approved IHC Companion Diagnostic for Prostate Cancer
NeoGenomics shares rose 3.4% after the company announced the launch of PTEN IHC CDx, the first FDA-approved immunohistochemistry companion diagnostic test for prostate cancer. The test identifies PTEN protein loss in prostate adenocarcinoma patients, helping determine eligibility for AstraZeneca's targeted therapy TRUQAP. The stock later settled at $14.68, up 3.1% from the previous close. NeoGenomics has gained 24.8% year-to-date and hit a new 52-week high.
USA